Kunming baker Norton pharmaceutical co., ltd. international cooperation.

KBN makes full use of its international background and market network advantages to carry out international cooperation with world-renowned pharmaceutical companies in the product field, continuously introduce and represent internationally renowned brand drugs, and introduce international high-end products into the China market. KBN has established cooperative relations with enterprises with international R&D advantages, such as TEVA in Israel, SKK in Japan, IVAX in the United States, PLIVA in Croatia and Findel in the United States, focusing on the screening, introduction and promotion of products in the fields of antibiotics, osteoporosis, osteoarthritis drugs, and drug treatment of children's respiratory infections.

Through the international cooperation mode in the product field, KBN has successfully introduced a series of first-line drugs for international clinical use, such as amoxicillin, alfa di San (soft capsules of alfa calcitol) and seaweed (sodium hyaluronate injection), occupying a leading share in the domestic drug treatment fields of antibiotics, osteoporosis and osteoarthritis, and enjoying professional brand awareness. On 20 10, KBN launched another "heavy" original drug-"Shumeite" (original azithromycin), which was regarded by the industry as a classic case of introducing high-end generic drugs into China. The introduction of this product will rewrite the competitive pattern of high-end antibiotic market in China. In addition, several new products launched by KBN, which are undergoing clinical research and application, are also "heavy" new drugs that are quite competitive in the field of orthopedic drugs in China. In the next three years, these new drugs will be "localized" in China, which will promote KBN's leap-forward development in business scale.